This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
by Urmimala Biswas
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
by Kinjel Shah
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
by Zacks Equity Research
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $73.55, signifying a -1.17% move from its prior day's close.
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
by Moumi Mondal
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies
by Zacks Equity Research
MSFT, AZN, and BLK lead Zacks' top stock picks, while TAYD and GEOS show resilience despite microcap market pressures.
Top Stock Reports for Microsoft, AstraZeneca & BlackRock
by Mark Vickery
MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
by Kinjel Shah
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $73.83, representing a +1.12% change from its previous close.
Is IonQ a Better Quantum Computing Stock to Buy Than D-Wave?
by Tirthankar Chakraborty
QTUM soars 42% in a year, led by IONQ and QBTS. Which quantum stock is the better buy?
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
by Urmimala Biswas
Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
by Zacks Equity Research
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
Danaher Partners With AstraZeneca to Support Precision Medicine
by Zacks Equity Research
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
by Kinjel Shah
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?
by Urmimala Biswas
BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.